Literature DB >> 10793058

Regulation of CD30 antigen expression and its potential significance for human disease.

M E Kadin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10793058      PMCID： PMC1876905          DOI： 10.1016/S0002-9440(10)65018-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  84 in total

1.  Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines.

Authors:  H J Gruss; N Boiani; D E Williams; R J Armitage; C A Smith; R G Goodwin
Journal:  Blood       Date:  1994-04-15       Impact factor: 22.113

2.  CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells.

Authors:  T M Ellis; P E Simms; D J Slivnick; H M Jäck; R I Fisher
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

Review 3.  The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death.

Authors:  C A Smith; T Farrah; R G Goodwin
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

Review 4.  Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines.

Authors:  H G Drexler
Journal:  Leuk Lymphoma       Date:  1993-01

5.  CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.

Authors:  C A Smith; H J Gruss; T Davis; D Anderson; T Farrah; E Baker; G R Sutherland; C I Brannan; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

6.  Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis.

Authors:  G Nadali; F Vinante; A Ambrosetti; G Todeschini; D Veneri; R Zanotti; V Meneghini; M M Ricetti; F Benedetti; A Vassanelli
Journal:  J Clin Oncol       Date:  1994-04       Impact factor: 44.544

7.  Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study of 47 patients.

Authors:  R C Beljaards; P Kaudewitz; E Berti; R Gianotti; C Neumann; R Rosso; M Paulli; C J Meijer; R Willemze
Journal:  Cancer       Date:  1993-03-15       Impact factor: 6.860

Review 8.  Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment.

Authors:  R Willemze; R C Beljaards
Journal:  J Am Acad Dermatol       Date:  1993-06       Impact factor: 11.527

9.  Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.

Authors:  H Dürkop; U Latza; M Hummel; F Eitelbach; B Seed; H Stein
Journal:  Cell       Date:  1992-02-07       Impact factor: 41.582

10.  CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection.

Authors:  R Manetti; F Annunziato; R Biagiotti; M G Giudizi; M P Piccinni; L Giannarini; S Sampognaro; P Parronchi; F Vinante; G Pizzolo; E Maggi; S Romagnani
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307
View more
  14 in total

1.  CD30+ lymphoproliferative disorders.

Authors:  Laurence de Leval; Philippe Gaulard
Journal:  Haematologica       Date:  2010-10       Impact factor: 9.941

2.  CD30 is a potential therapeutic target in malignant mesothelioma.

Authors:  Snehal Dabir; Adam Kresak; Michael Yang; Pingfu Fu; Gary Wildey; Afshin Dowlati
Journal:  Mol Cancer Ther       Date:  2015-01-14       Impact factor: 6.261

Review 3.  Breast implant-associated ALCL: a unique entity in the spectrum of CD30+ lymphoproliferative disorders.

Authors:  Sara K Story; Michael K Schowalter; Larisa J Geskin
Journal:  Oncologist       Date:  2013-02-21

4.  AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells.

Authors:  Mariko Watanabe; Yuji Ogawa; Kinji Ito; Masaaki Higashihara; Marshall E Kadin; Lawrence J Abraham; Toshiki Watanabe; Ryouichi Horie
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

5.  Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Sonia S Hassan; Francesca Gotsch; Samuel Edwin; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Shali Mazaki-Tovi; Eleazar Soto; Nandor Gabor Than; Lara A Friel; Bo Hyun Yoon; Jimmy Espinoza
Journal:  J Matern Fetal Neonatal Med       Date:  2007-12

6.  Co-expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor.

Authors:  R M Ruggeri; D Villari; A Simone; R Scarfi; M Attard; F Orlandi; G Barresi; F Trimarchi; M Trovato; S Benvenga
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

Review 7.  Hodgkin's lymphoma and CD30 signal transduction.

Authors:  Ryouichi Horie; Masaaki Higashihara; Toshiki Watanabe
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

8.  High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides.

Authors:  Marshall E Kadin; Igor Y Pavlov; Julio C Delgado; Eric C Vonderheid
Journal:  J Invest Dermatol       Date:  2011-11-10       Impact factor: 8.551

9.  Ber-H2 (CD30) immunohistochemical staining of human fetal tissues.

Authors:  D Tamiolakis; N Papadopoulos; M Lambropoulou; J Venizelos; D Verettas; P Tsikouras; G Koutsougeras; H Papadopoulos; A Karpouzis; C Kouskoukis
Journal:  Int J Biol Sci       Date:  2005-10-01       Impact factor: 6.580

10.  Human embryonal epithelial cells of the developing small intestinal crypts can express the Hodgkin-cell associated antigen Ki-1 (CD30) in spontaneous abortions during the first trimester of gestation.

Authors:  Demetrio Tamiolakis; John Venizelos; Maria Lambropoulou; Silva Nikolaidou; Sophia Bolioti; Maria Tsiapali; Dionysios Verettas; Panagiotis Tsikouras; Athanasios Chatzimichail; Nikolas Papadopoulos
Journal:  Theor Biol Med Model       Date:  2005-01-11       Impact factor: 2.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.